Estimación de la Relación Costo-Efectividad de las Vacunas Neumocócicas Conjugadas Prevenar-13 y Synflorix®, Utilizadas en Los Programas de Vacunación de Población Infantil Mexicana

Abstract

Even though the simulations for Prevenar-13 and Synflorix® revealed both of them to be cost-effective when used to instrument pediatric vaccination campaigns in Mexico, Synflorix® had a better cost-utility/effectiveness profile. In addition, although Prevenar-13 and Synflorix® produced equivalent health outcomes, the overall analysis predicted that Synflorix® would save 360 million Mexican pesos, as compared with Prevenar-13.

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico

“…A more recent analysis by Gomez and colleagues (2016) determined that PCV10 would be the cost-saving option compared to PCV13. 9 The results from this study however were driven entirely by the benefits of PCV10 preventing OM caused by non-typable Haemophillus influenza (NTHi) based on evidence from an investigational PCV11 vaccine. However, recent studies have shown PCV10 did not demonstrate any statistically significant effect on NTHi-clinically confirmed These scenarios assume that serotype replacement may take several years to occur given sustained use of PCV13 in years before switch.…”

“…Previous economic evaluations of PCVs in Mexico have a number of important limitations that this analysis improves upon. 8,9 An early study by Mucino-Ortega and colleagues (2010) determined PCV13 was cost-saving compared to PCV10. However this analysis did not consider the impact of herd effects.…”

“…Several studies have evaluated the cost-effectiveness of pneumococcal vaccines in Mexico, but none of them have considered the economic impact that a switch on the immunization program strategy from a higher to a lower valent vaccine would have. 8,9 The aim of this study was to estimate the retrospective public health and economic impact that pneumococcal vaccination with PCVs has had in Mexico from 2006 to 2014, the last year complete data were available, and to prospectively estimate the potential public health and economic impact of changing vaccine programs from a higher to lower valent vaccine.…”

Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada

“…By modeling each serotype individually by age group at a population level, this analysis more accurately estimates potential serotype replacement in the event of a vaccine switch. This methodology also provides a more realistic picture of how the vaccination programs may behave as it relies on real-world effectiveness data as opposed to the efficacy data used in most existing analyses [ 8 , 11 , 47 – 51 ]. This means that the forecasts inherently capture vaccine dynamics observed in the real world, such as vaccine waning, cross-reactivity, and herd protection.…”

“…An investigational 11-valent vaccine in which all serotypes were conjugated to protein D, a highly conserved protein from NTHi, showed statistically significant efficacy against all AOM episodes due to NTHi [ 60 , 61 ]. Previous economic analyses have assumed an additional benefit for PCV10 in preventing NTHi AOM based on evidence for this investigational 11-valent vaccine [ 47 , 50 , 51 , 62 , 63 ]. However, real-world effectiveness data published over the last few years have presented mixed evidence.…”